XML 44 R33.htm IDEA: XBRL DOCUMENT v3.21.1
Revenue - Additional Information (Details) - USD ($)
1 Months Ended 3 Months Ended
Mar. 31, 2021
Feb. 28, 2019
Mar. 31, 2021
Mar. 31, 2020
Disaggregation Of Revenue [Line Items]        
Revenue recognized $ 19,000,000.0   $ (21,351,000)  
Revenue from collaboration agreement     38,442,000 $ 20,910,000
MRD Development Agreements        
Disaggregation Of Revenue [Line Items]        
Milestone revenue recognized     7,000,000.0  
Revenue recognized     7,200,000 400,000
MRD Development Agreements | Maximum        
Disaggregation Of Revenue [Line Items]        
Additional milestone payment receivable 306,500,000   306,500,000  
Genentech Collaboration Agreement        
Disaggregation Of Revenue [Line Items]        
Non-refundable upfront payments received   $ 300,000,000.0 300,000,000.0  
Revenue from collaboration agreement     $ 15,600,000 $ 10,900,000
Genentech Collaboration Agreement | Maximum        
Disaggregation Of Revenue [Line Items]        
Revenue recognition expected period     8 years  
Genentech Collaboration Agreement | Maximum | Regulatory Milestones        
Disaggregation Of Revenue [Line Items]        
Expected revenue through milestone payments 75,000,000.0   $ 75,000,000.0  
Genentech Collaboration Agreement | Maximum | Development Milestones        
Disaggregation Of Revenue [Line Items]        
Expected revenue through milestone payments 300,000,000.0   300,000,000.0  
Genentech Collaboration Agreement | Maximum | Commercial Milestones        
Disaggregation Of Revenue [Line Items]        
Expected revenue through milestone payments 1,430,000,000.0   1,430,000,000.0  
Genentech Collaboration Agreement | Minimum        
Disaggregation Of Revenue [Line Items]        
Expected revenue through milestone payments $ 1,800,000   $ 1,800,000  
Revenue recognition expected period     7 years